Optimal Dosing of the Poly(ADP-Ribose) Polymerase Inhibitor Niraparib

May 29-31, 2020; Online at meetings.asco.org/am
Individualized dosing of niraparib based on weight and platelet count improves tolerability with no loss of efficacy.
Format: Microsoft PowerPoint (.ppt)
File Size: 212 KB
Released: June 1, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Related Content

Laurie Cohen, MD, on when and how to retest for GH deficiency, how soon to start GH replacement in cancer survivors from Clinical Care Options (CCO)

Laurie E. Cohen, MD Released: April 22, 2021

Danielle Friedman, MD, on adipose dysfunction, insulinopenia, obesity, and diabetes after irradiation in cancer survivors

Danielle N. Friedman, MD, MS Released: April 22, 2021

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2021, from Clinical Care Options (CCO)

Jubilee Brown, MD Ursula Matulonis, MD Released: April 8, 2021

Podcast episode with expert insights on new data from SGO 2021 in endometrial and ovarian cancers, from Clinical Care Options (CCO)

Jubilee Brown, MD Ursula Matulonis, MD Released: April 7, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue